{"product_id":"astrazeneca-bcg-matrix","title":"AstraZeneca Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAstraZeneca’s BCG Matrix preview highlights which therapeutic areas and franchises are acting as Stars, Cash Cows, Question Marks, or Dogs amid rapid biopharma shifts—spotlighting oncology strength and emerging respiratory assets. This snapshot shows where cash generation fuels R\u0026amp;D and where strategic divestment or investment might be needed. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel deliverables to guide investment and portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhertu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnhertu, AstraZeneca’s premier antibody-drug conjugate (ADC), posted explosive 2025 alliance revenue growth of 38% to about $12.6 billion, cementing a Star profile in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Enhertu is the standard of care for HER2-positive and HER2-low metastatic breast cancer after new first-line approvals, driving rapid uptake in the US and EU.\u003c\/p\u003e\n\u003cp\u003eOngoing heavy investment in trials for gastric and lung cancers keeps R\u0026amp;D spend high, matching the high-growth, high-share Star classification and positioning Enhertu as a future cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTezspire\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTezspire is a Star in AstraZeneca’s BCG matrix: severe-asthma biologic sales rose 65% to $1.13 billion in 2025, driving high revenue growth and strong market share.\u003c\/p\u003e\n\u003cp\u003eIt differentiates by treating a broad patient pool regardless of eosinophil biomarkers, expanding addressable market versus traditional eosinophilic biologics.\u003c\/p\u003e\n\u003cp\u003eHowever, Tezspire consumes heavy cash for global marketing and reimbursement against incumbents—pressuring margins and free cash flow in 2025.\u003c\/p\u003e\n\u003cp\u003eIf US and Japan adoption trends persist, Tezspire is likely to become a Cash Cow as the severe-asthma market matures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltomiris\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltomiris grew 16% in 2025 to $1.27 billion in quarterly sales after transitioning many patients from Soliris, securing a leading share in PNH and aHUS rare-disease markets.\u003c\/p\u003e\n\u003cp\u003eClassed as a Star, Ultomiris is gaining new indications and entering major markets like China, requiring sustained R\u0026amp;D and promotion to support growth.\u003c\/p\u003e\n\u003cp\u003eStrong patent protection through the 2030s underpins its leadership in AstraZeneca’s rare-disease portfolio and fuels the company’s 2030 revenue targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImfinzi\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImfinzi is AstraZeneca’s Star in the BCG matrix: it drove a 39% revenue jump to $1.75 billion in Q4 2025 and leads the unresectable Stage III non-small cell lung cancer market while rapidly gaining share in perioperative gastric and biliary tract cancers.\u003c\/p\u003e\n\u003cp\u003eHigh IO (immuno-oncology) segment growth makes Imfinzi a cash-consuming growth leader; AstraZeneca is funding large combo trials to defend and extend label, keeping it the primary driver of the company’s double-digit oncology growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 revenue: $1.75B (+39%)\u003c\/li\u003e\n\u003cli\u003eMarket leader: unresectable Stage III NSCLC\u003c\/li\u003e\n\u003cli\u003eFast share gains: perioperative gastric, biliary cancers\u003c\/li\u003e\n\u003cli\u003eRequires heavy R\u0026amp;D investment in combos\u003c\/li\u003e\n\u003cli\u003eKey driver of double-digit oncology growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreztri\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBreztri, AstraZeneca’s triple-therapy COPD inhaler, is a Star: 2025 sales rose 23% to about $1.2 billion, driven by leading fixed-dose combination (FDC) share in China and expanding US\/Europe rollout.\u003c\/p\u003e\n\u003cp\u003eIt generates strong cash but high launch and pricing pressures keep it in Stars; sustained investment in triple-threat efficacy data is critical to defend versus other respiratory majors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 sales ≈ $1.2B\u003c\/li\u003e\n\u003cli\u003e2025 growth +23%\u003c\/li\u003e\n\u003cli\u003eLeading FDC share in China\u003c\/li\u003e\n\u003cli\u003eHigh launch costs \u0026amp; pricing pressure\u003c\/li\u003e\n\u003cli\u003eOngoing clinical data investment required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBlockbuster lineup: Enhertu, Imfinzi, Tezspire, Ultomiris, Breztri drive strong 2025 growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Enhertu $12.6B (2025, +38%) — first-line HER2+\/-; Tezspire $1.13B (+65%) — broad severe asthma; Ultomiris $1.27B (+16%) — PNH\/aHUS leader; Imfinzi $1.75B (Q4 2025, +39%) — IO growth; Breztri $1.2B (+23%) — COPD FDC China leader.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 Rev\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnhertu\u003c\/td\u003e\n\u003ctd\u003e$12.6B\u003c\/td\u003e\n\u003ctd\u003e+38%\u003c\/td\u003e\n\u003ctd\u003eFirst-line HER2+\/HER2-low\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTezspire\u003c\/td\u003e\n\u003ctd\u003e$1.13B\u003c\/td\u003e\n\u003ctd\u003e+65%\u003c\/td\u003e\n\u003ctd\u003eBroad severe asthma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUltomiris\u003c\/td\u003e\n\u003ctd\u003e$1.27B\u003c\/td\u003e\n\u003ctd\u003e+16%\u003c\/td\u003e\n\u003ctd\u003ePNH\/aHUS leader\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImfinzi\u003c\/td\u003e\n\u003ctd\u003e$1.75B (Q4)\u003c\/td\u003e\n\u003ctd\u003e+39%\u003c\/td\u003e\n\u003ctd\u003eIO combos, perioperative gains\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreztri\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003ctd\u003e+23%\u003c\/td\u003e\n\u003ctd\u003eCOPD FDC, China lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG analysis of AstraZeneca’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest\/hold\/divest guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page AstraZeneca BCG Matrix placing each business unit in a quadrant for swift portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFarxiga\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFarxiga, AstraZeneca’s leading SGLT2 inhibitor, delivered over $2.06 billion in Q4 2025 with steady high-single-digit growth, making it a top cash cow.\u003c\/p\u003e\n\u003cp\u003eIt holds dominant market share in mature T2D, heart failure, and CKD markets, producing a reliable stream of high-margin cash.\u003c\/p\u003e\n\u003cp\u003eEstablished indications mean lower promotional spend than oncology, freeing free cash flow for R\u0026amp;D and to support AstraZeneca’s 2025 dividend payments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTagrisso\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTagrisso remains the backbone of AstraZeneca’s oncology segment, delivering roughly $1.9 billion in Q4 2025 sales as the established leader in EGFR‑mutated non‑small cell lung cancer.\u003c\/p\u003e\n\u003cp\u003eGrowth has stabilized at about 10–12% in mature markets, but high market share and lean manufacturing make it a classic Cash Cow.\u003c\/p\u003e\n\u003cp\u003eIts operating margins are among the highest in the portfolio, funding R\u0026amp;D and expansion into cell therapy programs.\u003c\/p\u003e\n\u003cp\u003eDespite impending patent cliffs, Tagrisso’s current dominance lets AstraZeneca milk substantial cash flow for reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLynparza\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLynparza, the first-in-class PARP inhibitor, generated $878 million in Q4 2025 sales and holds a leading share across ovarian, breast, prostate, and pancreatic cancers via AstraZeneca’s Merck partnership.\u003c\/p\u003e\n\u003cp\u003eGrowth slowed to 4% as the PARP market matures, but high share and low capex mean most revenue converts to operating profit, keeping Lynparza a cash cow for AstraZeneca’s oncology franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalquence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCalquence reached $967 million in Q4 2025 sales and grew 20% year-over-year, securing leadership in front-line CLL; its high market share in a stable therapeutic area marks it as a maturing Star shifting into the Cash Cow quadrant.\u003c\/p\u003e\n\u003cp\u003eThe drug delivers steady, high-margin cash flow thanks to an established safety-efficacy profile and strong physician loyalty, funding R\u0026amp;D for next-generation hematology assets in AstraZeneca’s pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 sales: $967M\u003c\/li\u003e\n\u003cli\u003eYoY growth: 20%\u003c\/li\u003e\n\u003cli\u003eStatus: maturing Star → Cash Cow\u003c\/li\u003e\n\u003cli\u003eRole: funds hematology R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eKey strength: high margins, physician loyalty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFasenra\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFasenra is a mature leader in severe eosinophilic asthma, delivering $530 million in Q4 2025 sales and sustaining a 12% growth rate, marking it as a high-share, low-growth product for AstraZeneca.\u003c\/p\u003e\n\u003cp\u003eIts convenient dosing and proven long-term safety keep strong specialist uptake; market saturation makes it a Cash Cow that generates steady free cash flow with optimized marketing spend.\u003c\/p\u003e\n\u003cp\u003eFasenra’s cash supports launches like Airsupra and expands AstraZeneca’s immunology portfolio, funding R\u0026amp;D and commercialization without large incremental investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 sales $530 million\u003c\/li\u003e\n\u003cli\u003e12% steady growth rate\u003c\/li\u003e\n\u003cli\u003eHigh specialist market share\u003c\/li\u003e\n\u003cli\u003eFunds Airsupra launch and immunology expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh‑margin cash engines: Farxiga $2.06B, Tagrisso $1.9B fuel R\u0026amp;D \u0026amp; launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFarxiga $2.06B Q4 2025; Tagrisso $1.9B; Lynparza $878M; Calquence $967M; Fasenra $530M — high-share, low-growth assets generating strong operating margins and free cash flow to fund R\u0026amp;D, dividends, and new launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eQ4 2025 Sales\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFarxiga\u003c\/td\u003e\n\u003ctd\u003e$2.06B\u003c\/td\u003e\n\u003ctd\u003ehigh‑single‑digit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTagrisso\u003c\/td\u003e\n\u003ctd\u003e$1.9B\u003c\/td\u003e\n\u003ctd\u003e10–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLynparza\u003c\/td\u003e\n\u003ctd\u003e$878M\u003c\/td\u003e\n\u003ctd\u003e~4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCalquence\u003c\/td\u003e\n\u003ctd\u003e$967M\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFasenra\u003c\/td\u003e\n\u003ctd\u003e$530M\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eAstraZeneca BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact AstraZeneca BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748067520889,"sku":"astrazeneca-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/astrazeneca-bcg-matrix.png?v=1772204399","url":"https:\/\/matrixbcg.com\/products\/astrazeneca-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}